Chronic hepatitis B (HBV) imposes a significant disease burden and identifying those at-risk for HBV is imperative to implementing effective care. More than half of people living with HBV are of Asian, Pacific Islander, or African descent, and HBV and the resulting hepatocellular cancer (HCC) contribute to substantial health disparities for these groups. While HBV is not curable, early detection, treatment, and monitoring can reduce the risk of liver disease and HCC.
Test your knowledge during this interactive CME Outfitters Live and OnDemand webcast featuring augmented reality animations that will reinforce the fibrotic consequence of untreated HBV. Data presentation and translation will showcase the importance of implementing routine screening protocols, optimizing efficacy and safety profiles of current agents when initiating or switching treatment, and routinely monitoring patients with HBV for disease progression HCC, and HBV reactivation.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
Supported by an educational grant from Gilead Sciences, Inc.
Primary care physicians, nurse practitioners, PAs, nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Kowdley reports that he receives research support from Janssen Pharmaceuticals, Inc. He is on the speakers bureau for Gilead Sciences, Inc. He is a consultant for Altimmune.
Dr. Lim reports he received research support from Allergan; Celgene Corporation; Eiger BioPharmaceuticals; GENFIT; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.
Dr. Wang has no disclosures to report
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Noreen Iftikhar, MD (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.